Poster Authors:

Filipa Antunes¹, Jia Jia², Zhengxing Qu², Jing Lai², XiaotingFan², Yuping Liu², Chunyan Han², Barry Jones¹, Mandy Xu²

¹Pharmaron UK, Innovation Park, West Cl, Hertford Rd, Hoddesdon EN11 9FH, United Kingdom

²Pharmaron China, Beijing: 6 Taihe Road, BDA, Beijing, 100176

Permeability Assay Platform for Evaluating P?gp Efflux and Transport

Elevate your drug development process with Pharmaron’s specialized permeability assay platform, designed to precisely evaluate small molecule permeability and P-glycoprotein (P-gp) substrate properties. Using CRISPR/Cas9 technology, our MDCKII cell lines with targeted canine MDR1 knockout and transfected human, monkey, and mouse MDR1 genes provide accurate models for studying efflux activity and blood-brain barrier predictions.

Key takeaways from this poster include:

• Advanced Cell Line Engineering: Leverage our canine MDR1-knockout and MDR1-transfected cell lines for reliable insights into efflux liability across species-specific P-gp.
• Comprehensive Testing Capabilities: Evaluate compounds with our robust methodologies, including efflux ratio assessments and P-gp inhibition studies using PSC833.
• Data-Driven Insights: Analyze transport mechanisms with detailed permeability and efflux data for compounds like propranolol, quinidine, and digoxin.

Pharmaron’s permeability assay platform ensures high-quality, reproducible data, enabling informed decisions for both early-stage screening and complex mechanistic studies.